Skip to Content

HPV Persistence and Progression Cohort (PaP Cohort)

DCEG investigators teamed with Kaiser Permanente Northern California (KPNC) to create a repository of specimens with carcinogenic HPV genotypes that would be useful for natural history studies of HPV typing, methylation, and HPV variant genomics. KPNC routinely uses an FDA-approved pooled-type DNA test for carcinogenic HPV (HC2) with cytology (“cotesting”) for cervical cancer screening in women 30 and older. 

Investigators have stored approximately 35,000 baseline specimens that have tested positive by HC2 and 5,000 specimens that have tested negative by HC2.  They have genotyped specimens selected for testing based on clinical outcomes ascertained by linkage to the KPNC cytology and histology databases and KPNC's active yearly follow-up of all HC2-positive women. The investigators will "follow" women for three years after enrollment ending in 2011 by banking their residual specimens collected at their return visits.  At present, there are more than 100,000 stored specimens, with 20,000 typed.

For more information, contact Mark Schiffman.

Clinical Genetics Branch - Research Areas